News | November 12, 2021
Covaxin well tolerated with no safety concerns: Lancet
Covaxin is the only Covid-19 vaccine to have demonstrated efficacy data from phase III clinical trials against the Delta variant at 65.2%
Covaxin is the only Covid-19 vaccine to have demonstrated efficacy data from phase III clinical trials against the Delta variant at 65.2%
The submission is based on Phase 2/3 study of mRNA-1273 in children ages 6 to 11
Molnupiravir is an investigational oral antiviral medicine, for the treatment of mild-to-moderate COVID-19 in at risk adults
Shaan’s hit song `Tanha Dil Tanha Safar relaunched
Cipla Technologies a subsidiary of Cipla and Pulmatrix had inked a definitive agreement for the co-development and commercialisation of Pulmazole.
It was recognized for its holistic initiatives designed to improve the quality of life and standards of care for patients
The workshop had been organized by the department of surgery at Jawaharlal Nehru Medical College (JNMC), Aligarh Muslim University (AMU), along with the Association of Surgeons of Aligarh (ASA)
Bioanalytical approach to accelerate development efforts in the identification of compounds that can treat chlorine or sulfur mustard injuries
A Sanofi R&D executive will join the Gyroscope Clinical Advisory Board to advise on matters related to the development of GT005 for geographic atrophy (GA).
Divi's Laboratories Limited has reported consolidated financial results for the period ended September 30, 2021.
Subscribe To Our Newsletter & Stay Updated
